ADMA BIOLOGICS, INC. Deferred Federal Income Tax Expense (Benefit)
ADMA BIOLOGICS, INC. (ADMA) reported Deferred Federal Income Tax Expense (Benefit) of $9.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-25
- ADMA BIOLOGICS, INC. deferred federal income tax expense (benefit) for fiscal 2025 was $9.38M.
- ADMA BIOLOGICS, INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$72.86M.
- ADMA BIOLOGICS, INC. deferred federal income tax expense (benefit) for fiscal 2023 was $0.00.
- ADMA BIOLOGICS, INC. deferred federal income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $9.38M 10-K · filed 2026-02-25 |
| 2024-12-31 | -$72.86M 10-K · filed 2026-02-25 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |